Virogentics and Enzolytics Refute Misleading Information Being Circulated on Social Media and Other Internet Outlets Biogenesis to be Featured in June Issue of Life Science Review

COLLEGE STATION, TX / ACCESSWIRE / May 19, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) Enzolytics wants to inform its shareholders that the ownership of the Company's patented technology is held exclusively in the name of The Zhabilov Trust, with Diana Zhabilov serving as the trustee of the trust. This ownership is verified by a review of the records filed with the USPTO and shown on the USPTO web site www.uspto.gov. Virogentics, a subsidiary of Enzolytics, is the exclusive licensee for ITV-1 and the exclusive licensee in the U.S. and most world countries of IPF Immune. Claims made by any other company or individual is false.

Ownership of the Zhabilov Patents may be verified by a search of the Patent Assignment records in the U.S. Patent and Trademark Office at: https://assignments.uspto.gov/assignments/?db=pat

These records verify ownership of the subject patent is held in the name of The Zhabilov Trust.

For U.S. Patent No. 7479538

https://assignments.uspto.gov/assignments/q?db=pat&qt=pat&reel=&frame= ...

For U.S. Patent No. 8066982

https://assignments.uspto.gov/assignments/q?db=pat&qt=pat&reel=&frame= ...

For U.S. Patent No. 8309072

https://assignments.uspto.gov/assignments/q?db=pat&qt=pat&reel=&frame= ...

To further address the misinformation, Enzolytics and Virogentic want to inform their shareholders that all the licenses between Immunotech USA and Immunotech BG were canceled because of lack of performance by Immunotech BG, tortious interference by Mr. Savov the CEO of IMMB BG and by virtue of time limitations embodied directly in the licenses.

In addition, the Company strongly believes that, in consort with the individuals posting lies and misinformation on Twitter with the handle "Stocks and Stones" and on other social media, Nika Pharmaceuticals is making false claims on its website and in SEC filings.

The Company would also like to disclose that it is being featured in Life Science Review Magazine June issue as the most innovative monoclonal antibody company with a special mention of its AI platform and Monoclonal Antibody methodology.

Harry Zhabilov, CSO of Virogentics stated, "It is a shame that the individuals and entities are making false claims and these misinformation statements are allowed to continue to spread such disinformation. We are investigating what actions we can take in the courts and through regulatory agencies. ENZC and Virogentics has made tremendous progress in its goal of bringing ITV-1 to market. Human clinical trials are slated to begin this summer in Africa."